PURPOSE: The type I Melanoma Antigen GEnes (MAGEs) are commonly expressed in cancers, fueling speculation that they may be therapeutic targets with oncogenic potential. They form complexes with RING domain proteins that have E3 ubiquitin ligase activity and promote p53 degradation. MAGE-A3 was detected in tumor specimens from patients with multiple myeloma and its expression correlated with higher frequencies of Ki-67(+) malignant cells. In this report, we examine the mechanistic role of MAGE-A in promoting survival of proliferating multiple myeloma cells. EXPERIMENTAL DESIGN: The impact of MAGE-A3 expression on survival and proliferation in vivo was examined by immunohistochemical analysis in an independent set of tumor specimens segregated into two groups: newly diagnosed, untreated patients and patients who had relapsed after chemotherapy. The mechanisms of MAGE-A3 activity were investigated in vitro by silencing its expression by short hairpin RNA interference in myeloma cell lines and primary cells and assessing the resultant effects on proliferation and apoptosis. RESULTS: MAGE-A3 was detected in a significantly higher percentage of relapsed patients compared with newly diagnosed, establishing a novel correlation with progression of disease. Silencing of MAGE-A showed that it was dispensable for cell cycling, but was required for survival of proliferating myeloma cells. Loss of MAGE-A led to apoptosis mediated by p53-dependent activation of proapoptotic Bax expression and by reduction of survivin expression through both p53-dependent and -independent mechanisms. CONCLUSIONS: These data support a role for MAGE-A in the pathogenesis and progression of multiple myeloma by inhibiting apoptosis in proliferating myeloma cells through two novel mechanisms.
PURPOSE: The type I Melanoma Antigen GEnes (MAGEs) are commonly expressed in cancers, fueling speculation that they may be therapeutic targets with oncogenic potential. They form complexes with RING domain proteins that have E3 ubiquitin ligase activity and promote p53 degradation. MAGE-A3 was detected in tumor specimens from patients with multiple myeloma and its expression correlated with higher frequencies of Ki-67(+) malignant cells. In this report, we examine the mechanistic role of MAGE-A in promoting survival of proliferating multiple myeloma cells. EXPERIMENTAL DESIGN: The impact of MAGE-A3 expression on survival and proliferation in vivo was examined by immunohistochemical analysis in an independent set of tumor specimens segregated into two groups: newly diagnosed, untreated patients and patients who had relapsed after chemotherapy. The mechanisms of MAGE-A3 activity were investigated in vitro by silencing its expression by short hairpin RNA interference in myeloma cell lines and primary cells and assessing the resultant effects on proliferation and apoptosis. RESULTS:MAGE-A3 was detected in a significantly higher percentage of relapsed patients compared with newly diagnosed, establishing a novel correlation with progression of disease. Silencing of MAGE-A showed that it was dispensable for cell cycling, but was required for survival of proliferating myeloma cells. Loss of MAGE-A led to apoptosis mediated by p53-dependent activation of proapoptotic Bax expression and by reduction of survivin expression through both p53-dependent and -independent mechanisms. CONCLUSIONS: These data support a role for MAGE-A in the pathogenesis and progression of multiple myeloma by inhibiting apoptosis in proliferating myeloma cells through two novel mechanisms.
Authors: Martin Monte; Marta Simonatto; Leticia Y Peche; Debora R Bublik; Stefania Gobessi; Marco A Pierotti; Monica Rodolfo; Claudio Schneider Journal: Proc Natl Acad Sci U S A Date: 2006-07-17 Impact factor: 11.205
Authors: Andrew J G Simpson; Otavia L Caballero; Achim Jungbluth; Yao-Tseng Chen; Lloyd J Old Journal: Nat Rev Cancer Date: 2005-08 Impact factor: 60.716
Authors: E De Plaen; K Arden; C Traversari; J J Gaforio; J P Szikora; C De Smet; F Brasseur; P van der Bruggen; B Lethé; C Lurquin Journal: Immunogenetics Date: 1994 Impact factor: 2.846
Authors: Bing Yang; Sean M O'Herrin; Jianqiang Wu; Shannon Reagan-Shaw; Yongsheng Ma; Kumar M R Bhat; Claudia Gravekamp; Vijayasaradhi Setaluri; Noel Peters; F Michael Hoffmann; Hongzhuang Peng; Alexey V Ivanov; Andrew J G Simpson; B Jack Longley Journal: Cancer Res Date: 2007-10-15 Impact factor: 12.701
Authors: Johannes A Veit; Daniela Heine; Julia Thierauf; Jochen Lennerz; Subasch Shetty; Patrick J Schuler; Theresa Whiteside; Dirk Beutner; Moritz Meyer; Inga Grünewald; Gerd Ritter; Sacha Gnjatic; Andrew G Sikora; Thomas K Hoffmann; Simon Laban Journal: Head Neck Date: 2016-02-13 Impact factor: 3.147
Authors: S Hartmann; U Kriegebaum; N Küchler; R C Brands; C Linz; A C Kübler; U D A Müller-Richter Journal: Clin Oral Investig Date: 2013-02-21 Impact factor: 3.573
Authors: Evelyne Lerut; Hendrik Van Poppel; Steven Joniau; Olivier Gruselle; Thierry Coche; Patrick Therasse Journal: Int J Clin Exp Pathol Date: 2015-08-01
Authors: Stefan Hartmann; Leonie Zwick; Mario J J Scheurer; Andreas R Fuchs; Roman C Brands; Axel Seher; Hartmut Böhm; Alexander C Kübler; Urs D A Müller-Richter Journal: Clin Oral Investig Date: 2017-10-15 Impact factor: 3.573
Authors: Neehar Bhatia; Tony Z Xiao; Kimberly A Rosenthal; Imtiaz A Siddiqui; Saravanan Thiyagarajan; Brendan Smart; Qiao Meng; Cindy L Zuleger; Hasan Mukhtar; Shannon C Kenney; Mark R Albertini; B Jack Longley Journal: J Invest Dermatol Date: 2012-10-25 Impact factor: 8.551
Authors: Rebecca R Florke Gee; Helen Chen; Anna K Lee; Christina A Daly; Benjamin A Wilander; Klementina Fon Tacer; Patrick Ryan Potts Journal: J Biol Chem Date: 2020-09-13 Impact factor: 5.157